跳转至内容
Merck
CN

376817

Sigma-Aldrich

1-(2,3,5,6-四氟苯基)咪唑

99%

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C9H4F4N2
化学文摘社编号:
分子量:
216.14
MDL编号:
UNSPSC代码:
12352100
PubChem化学物质编号:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

方案

99%

mp

92-94 °C (lit.)

SMILES字符串

Fc1cc(F)c(F)c(c1F)-n2ccnc2

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Xiaodong Zhang et al.
Anticancer research, 29(4), 1443-1448 (2009-05-06)
Most cancer cells exhibit increased anaerobic glycolysis and use this metabolic pathway for the generation of ATP as a main source of energy. This impaired metabolism of glucose, leading to the secretion of lactic acid even in the presence of
Saroj P Mathupala et al.
Seminars in cancer biology, 19(1), 17-24 (2008-12-23)
The most common metabolic hallmark of malignant tumors, i.e., the "Warburg effect" is their propensity to metabolize glucose to lactic acid at a high rate even in the presence of oxygen. The pivotal player in this frequent cancer phenotype is
Esther Hulleman et al.
Blood, 113(9), 2014-2021 (2008-11-04)
Treatment failure in pediatric acute lymphoblastic leukemia (ALL) is related to cellular resistance to glucocorticoids (eg, prednisolone). Recently, we demonstrated that genes associated with glucose metabolism are differentially expressed between prednisolone-sensitive and prednisolone-resistant precursor B-lineage leukemic patients. Here, we show
Ji Su Kim et al.
Journal of bioenergetics and biomembranes, 40(6), 607-618 (2008-12-11)
Hexokinase type II (HK II) is the key enzyme for maintaining increased glycolysis in cancer cells where it is overexpressed. 3-bromopyruvate (3-BrPA), an inhibitor of HK II, induces cell death in cancer cells. To elucidate the molecular mechanism of 3-BrPA-induced
Axel-R Hanauske et al.
Investigational new drugs, 27(4), 356-365 (2008-10-29)
The objectives of this phase I study were to determine the maximum tolerated dose (MTD), recommended phase II dose (RD), antitumor activity, safety, and pharmacokinetics of pemetrexed-paclitaxel combination. Patients (N = 95) with advanced solid tumors were assigned to three

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持